



Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings

Sep 21 2021, 4:01 PM EDT

Abeona Therapeutics to Present at Upcoming Investor Conferences

Sep 7 2021, 7:30 AM EDT

Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer

Aug 10 2021, 7:30 AM EDT

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	119.45m
Last Price	\$1.18
52-Week	\$0.9895 - \$3.7899

09/27/2021 04:00 PM EDT

Investor Relations

ir@abeonatherapeutics.com

Management Team

Michael Amoroso

President, Chief Executive Officer

Vishwas Seshadri, Ph.D., M.B.A.

Senior Vice President, Head of Research & Clinical Development

Edward Carr

Chief Financial Officer, Principal Financial Officer

Greg Gin

Vice President, Investor Relations and Corporate Communications

Brian Kevany, Ph.D.

Vice President, Chief Technical Officer

Kristina Maximenko

Vice President, Human Resources

Scott Nogi

Vice President, Business Operations

Brendan O'Malley, J.D., Ph.D.

Senior Vice President, General Counsel

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.